Skip to content

ADenoVirus Initiative Study in Epidemiology in UK

Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02112773
Enrollment
31
Registered
2014-04-14
Start date
2015-02-28
Completion date
2015-06-30
Last updated
2015-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral Conjunctivitis

Keywords

Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test

Brief summary

The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.

Detailed description

Epidemiological, prospective, open, multicentric trial in patients suffering from acute conjunctivitis who will undergo a rapid diagnostic test for adenoviral conjunctivitis at the time of their visit to the ophthalmologist office, at the emergency room or during hospitalization. This epidemiological study will include approximately 500 patients in the United Kingdom. The planned duration of the study is one year from the first patient visit to the last patient visit.

Interventions

None listed

Sponsors

NicOx
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or Female patients of at least one year of age presenting acute (for less than 7 days) conjunctivitis signs and symptoms. * Patient or / and legal representative (if patient below 18 years of age) must be able to provide oral consent for the collection and treatment of the questionnaire data. * No history of hypersensitivity to corn starch, talcum powder or Dacron (sampling fleece components).

Exclusion criteria

* Current use or having received (within the last 7 days) local antiviral therapies such as povidone iodine or ganciclovir, or topical steroids or immunomodulators such as cyclosporine which may interfere with the test result. * Previous enrolment in the present study. * Any direct involvement with the study conduct at site or any family link with study site staff.

Design outcomes

Primary

MeasureTime frameDescription
Frequency of patients with adenovirus conjunctivitisDuring the visit to the ophthalmologist before and just after the AdenoPlus® test done on the same day (one visit)The percentage of patients with adenovirus conjunctivitis documented by a positive AdenoPlus® test over the tested population of male and female patients who present signs and symptoms of acute conjunctivitis.

Other

MeasureTime frameDescription
Seasonality and geographic repartition observed.During the visit to the ophthalmologist before and just after the AdenoPlus® test done on the same day (one visit)The number of patients with adenovirus conjunctivitis who visited the ophthalmologist in spring, summer, autumn and winter and their geographic area (e.g. by hospital, by area).
Clinical profiles of the patientsDuring the visit to the ophthalmologist before and just after the AdenoPlus® test done on the same day (one visit)The percentage of each eye signs and symptoms, the mean duration of the disease for both the patients with positive and negative AdenoPlus® tests, the number or follow-up visit done and the correlation between the initial diagnosis (before AdenoPlus® test results) and the final diagnosis (post AdenoPlus® test results).
Resource utilization during the treatment and evaluation of the costsOn day 1: at least once during the single visit to the ophthalmologist and if any also during the follow-up visit(s)Estimation of resource utilized during course of treatment (use of drugs, number of visits done by the patient…), and associated costs (which would be calculated by applying unit costs to resource use).
Patient/parent absenteeism linked to this disease.On day 1: at least once during the single visit to the ophthalmologist and if any also during the follow-up visit(s)Number of days out of work and/or out of school linked to this disease.
Safety assessmentOn day 1: at least once during the single visit to the ophthalmologist and if any also during the follow-up visit(s)Number of adverse incidents (AIs) and events that are of significant (SEs) reported to Nicox

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026